MARKSANS2024-10-012024-12-31 MARKSANS2024-10-012024-12-31 MARKSANS2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member MARKSANS2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member MARKSANS2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524404 MARKSANS NOTLISTED Marksans Pharma Limited Equity 2024-04-01 2025-03-31 2025-02-11 2025-01-22 INR Millions Third quarter 19:15:00 20:00:00 2025-02-11 2025-02-11 Not applicable Single segment Manufacturing & Marketing of Pharmaceutical Formulations 2024-10-01 2024-12-31 Unaudited Standalone 3118650000.00 225080000.00 3343730000.00 1412730000.00 233300000.00 56320000.00 257540000.00 3040000.00 74220000.00 559360000.00 2596510000.00 747220000.00 0.00 747220000.00 176170000.00 16420000.00 192590000.00 0.00 554630000.00 0.00 0.00 0.00 0.00 554630000.00 710000.00 555340000.00 555340000.00 0.00 453164000.00 1 1.22 1.22 0.00 0.00 1.22 1.22 1. The unaudited standalone financial results for the quarter and nine months ended 31 December 2024 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 11 February 2025. The Statutory Auditors of the Company have carried out limited review on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended and expressed an unmodified conclusion. 2. The unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulation. 3. The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'. 4. As at 31 December 2024, following are the direct and indirect subsidiaries of the Company: ·         Marksans Pharma (UK) Limited ·         Relonchem Limited ·         Marksans Holdings Limited ·         Bell, Sons and Co. (Druggists) Limited ·         Marksans Pharma Inc. ·         Time-Cap Laboratories Inc. ·         Marise Ann Inc. ·         Custom Coating Inc. ·         Marksans Realty LLC ·         Nova Pharmaceuticals Australasia Pty Ltd ·         Nova Pharmaceuticals Limited ·         Access Healthcare for Medical Products L.L.C ·         Marksans Pharma GmbH Refer statement of unaudited consolidated financial results for the quarter and nine months ended 31 December 2024 which is published by the Company. 5. The above unaudited standalone financials results are available on the Company's website (www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 8750170000.00 620170000.00 9370340000.00 3921170000.00 852930000.00 -16020000.00 728590000.00 8630000.00 212750000.00 1728720000.00 7436770000.00 1933570000.00 0.00 1933570000.00 405860000.00 20890000.00 426750000.00 0.00 1506820000.00 0.00 0.00 0.00 0.00 1506820000.00 2120000.00 1508940000.00 1508940000.00 0.00 453164000.00 1 3.33 3.33 0.00 0.00 3.33 3.33 Other expenses 559360000.00 Other expenses 1728720000.00 950000.00 2840000.00 240000.00 720000.00